Meredith Hay
Works at
17 Sept 2026reporter.nih.gov
Professor27 Aug 2026reporter.nih.gov
Grants and prizes
Scale-up GMP Manufacturing of Extended-Release PNA5 for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular DementiaR43AG09931617 Sept 2026reporter.nih.gov
UG3PNA5 For Treatment of Vascular Cognitive Impairment and Dementia (VCID) and Alzheimer's disease related dementias (ADRD): A Phase 1a Safety and Tolerability StudyUG3AG1046422026–202727 Aug 2026reporter.nih.gov
U01PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology StudyU01AG0826172023–202713 Aug 2026reporter.nih.gov
U01PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology StudyU01AG0826172023–202716 Jul 2026reporter.nih.gov